US4470962A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polymeric diffusion matrix
Assignee: Key Pharmaceuticals Inc
•
Filing: 1981-04-28
•
Granted: 1984-09-11
•
Expires: 2001-04-28
Abstract
Abstract A polymeric diffusion matrix is provided comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinylalcohol, from about 2 to about 10% water soluble polymer with hydration sites which in combination with the remaining ingredients yields a matrix capable of sustained release of a drug dispersed therein, and the balance water, the percentages being by weight.
Inventors
- 👤 Alec D. Keith
- 👤 Wallace Snipes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 14:04
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/56; A61K31/565
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
85 words
A transdermal drug delivery vehicle, which contains α-[1-(methylamino)ethyl]benzene-methanol in the form of a shape-retaining matrix for direct application to the skin of a patient in need of the α-[1-(methylamino)ethyl]benzene-methanol to be delivered, said matrix comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinylalcohol molecular weight of from about 100,000 to about 150,000, from about 2 to about 10% polyvinylpyrrolidone molecular weight of from about 20,000 to about 60,000 and the balance water, cast or molded from hot solution thereof.
Claim 2
Dependent Claim
85 words
A transdermal drug delivery vehicle, which contains α-[1-(methylamino)ethyl]benzene-methanol in the form of a shape-retaining matrix for direct application to the skin of a patient in need of the α-[1-(methylamino)ethyl]benzene-methanol to be delivered, said matrix comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinylalcohol molecular weight of from about 100,000 to about 150,000, from about 2 to about 10% polyvinylpyrrolidone molecular weight of from about 20,000 to about 60,000 and the balance water, cast or molded from hot solution thereof.
Claim 3
Dependent Claim
28 words
A transdermal drug delivery vehicle according to claim 1 in combination with an occlusive backing layer for holding the matrix against the skin of the patient being treated.
Claim 4
Dependent Claim
22 words
A transdermal drug delivery vehicle accoring to claim 1 wherein the matrix is placed in a cavity in an inert backing material.
Claim 5
Dependent Claim
19 words
A transdermal drug delivery vehicle according to claim 3 wherein the matrix is molded in situ in the cavity.
Claim 6
Independent Claim
109 words
A method of delivering α-[1-(methylamino)ethyl]benzene-methanol to a patient over a prolonged period of time at a steady rate which comprises applying to the skin of said patient a transdermal drug delivery vehicle, which contains α-[1-(methylamino)ethyl]benzene-methanol in the form of a shape-retaining matrix for direct application to the skin of a patient in need of α-[1-methylamino)ethyl]benzene-methanol, said matrix comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinyl alcohol molecular weight of from about 100,000 to about 150,000, from about 2 to about 10% polyvinylpyrrolidone molecular weight of from about 20,000 to about 60,000 and the balance water, cast or molded from hot solution thereof.
Claim 7
Independent Claim
109 words
A method of delivering α-[1-(methylamino)ethyl]benzene-methanol to a patient over a prolonged period of time at a steady rate which comprises applying to the skin of said patient a transdermal drug delivery vehicle, which contains α-[1-(methylamino)ethyl]benzene-methanol in the form of a shape-retaining matrix for direct application to the skin of a patient in need of α-[1-methylamino)ethyl]benzene-methanol, said matrix comprising from about 2 to about 60% glycerol, from about 2 to about 15% polyvinyl alcohol molecular weight of from about 100,000 to about 150,000, from about 2 to about 10% polyvinylpyrrolidone molecular weight of from about 20,000 to about 60,000 and the balance water, cast or molded from hot solution thereof.
Claim 8
Dependent Claim
31 words
A method according to claim 5 wherein the transdermal drug delivery vehicle is attached to an occlusive backing layer for holding the matrix against the skin of the patient being treated.
Claim 9
Dependent Claim
19 words
A method according to claim 6 wherein the matrix is located in a cavity in an inert backing material.
References Cited (Backward Citations)
US1280149A
Cited
GB202161A
Cited
US2138751A
Cited
US2155658A
Cited
US2160503A
Cited
US2127896A
Cited
US2340866A
Cited
US2491642A
Cited
US2726982A
Cited
US2693438A
Cited
US2698822A
Cited
US2830370A
Cited
GB933668A
Cited
US3287222A
Cited
FR1505318A
Cited
US3249109A
Cited
US3339546A
Cited
US3429308A
Cited
US3426754A
Cited
US3214338A
Cited
GB1090184A
Cited
US3444858A
Cited
SU219116A1
Cited
GB1108837A
Cited
US3520949A
Cited
US3627871A
Cited
US3608070A
Cited
US3803300A
Cited
FR2245161A6
Cited
US3892905A
Cited
GB1343374A
Cited
US3789119A
Cited
US3729996A
Cited
JPS4892522A
Cited
JPS4930525A
Cited
JPS4945952A
Cited
JPS4948728A
Cited
GB1427881A
Cited
JPS5056385A
Cited
US4091091A
Cited
JPS50112511A
Cited
US4059686A
Cited
US3972995A
Cited
JPS5238016A
Cited
JPS5350320A
Cited
US4210633A
Cited
US4292299A
Cited
EP0013606B1
Cited
US4226848A
Cited
US4291015A
Cited
US4292301A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-11 | 1988-03-12 | 1988-09-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-11 | 1992-03-12 | 1992-09-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-11 | 1996-03-12 | 1996-09-11 | $7700.00 | Window Closed / Lapsed |